It is worthwhile to investigate the anticancer activity of Cu E in colorectal cancer and pancreatic ductal adenocarcinoma, given that KRAS mutations are prevalent in these malignancies [51]. Here, KRAS is linked to pancreatic ductal adenocarcinoma.